Sarcoidosis other diagnostic studies: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
 
(5 intermediate revisions by the same user not shown)
Line 5: Line 5:


==Overview==
==Overview==
The diagnosis of [[sarcoidosis]] requires a tissue biopsy, with the exception of rare circumstances which the clinical findings are highly specific [[sarcoidosis]].
The diagnosis of [[sarcoidosis]] requires a tissue biopsy, with the exception of rare circumstances which the clinical findings are highly specific for [[sarcoidosis]]. The evaluation of pulmonary disease in [[sarcoidosis]] patients relies on three major factors: pulmonary function, chest imaging, and symptoms.  


==Tissue biopsy==
==Tissue biopsy==
The diagnosis of [[sarcoidosis]] requires a tissue [[biopsy]], with the exception of rare circumstances which the clinical findings are highly specific for [[sarcoidosis]]. It is ideal for [[biopsy]] to be minimally invasive and associated with the least [[morbidity]]. Thus, peripheral [[biopsy]] sites are preferred compared to [[visceral]] organs<ref name="sar">Teirstein AS, Judson MA, Baughman RP, et al: The spectrum of biopsy sites for the diagnosis of sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 22(2):139 146, 2005.</ref>.When there is no evidence that a superficial peripheral site is involved by sarcoidosis, a [[biopsy]] is usually performed in organs which is very often the lung, because the lungs are involved in 90% of [[sarcoidosis]] patients<ref>Baughman RP, Teirstein AS, Judson MA, et al: Clinical characteristics of patients in a case control study of sarcoidosis. Am J Respir Crit Care Med 164:1885–1889, 2001.</ref>.
The diagnosis of [[sarcoidosis]] requires a tissue [[biopsy]], with the exception of rare circumstances which the clinical findings are highly specific for [[sarcoidosis]]<ref name="ex">Judson MA: The diagnosis of sarcoidosis. Clin Chest Med 29(3):415– 427, 2008.</ref>. It is ideal for [[biopsy]] to be minimally invasive and associated with the least [[morbidity]]. Thus, peripheral [[biopsy]] sites are preferred compared to [[visceral]] organs<ref name="sar">Teirstein AS, Judson MA, Baughman RP, et al: The spectrum of biopsy sites for the diagnosis of sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 22(2):139 146, 2005.</ref>.When there is no evidence that a superficial peripheral site is involved by sarcoidosis, a [[biopsy]] is usually performed in organs which is very often the lung, because the lungs are involved in 90% of [[sarcoidosis]] patients<ref>Baughman RP, Teirstein AS, Judson MA, et al: Clinical characteristics of patients in a case control study of sarcoidosis. Am J Respir Crit Care Med 164:1885–1889, 2001.</ref>.


===[[Bronchoscopy]]===  
===[[Bronchoscopy]]===  
Line 31: Line 31:
===Extrapulmonary tissue biopsy===
===Extrapulmonary tissue biopsy===
Granulomas can be detected in any organ which is involved by sarcoidosis<ref name="sar">Teirstein AS, Judson MA, Baughman RP, et al: The spectrum of biopsy sites for the diagnosis of sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 22(2):139 146, 2005.</ref>
Granulomas can be detected in any organ which is involved by sarcoidosis<ref name="sar">Teirstein AS, Judson MA, Baughman RP, et al: The spectrum of biopsy sites for the diagnosis of sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 22(2):139 146, 2005.</ref>
==When the diagnosis can be made without performing a tissue biopsy?==
in some clinical scenarios, the presentation is so specific that the diagnosis can be made without a confirmatory tissue biopsy<ref name="ex">Judson MA: The diagnosis of sarcoidosis. Clin Chest Med 29(3):415– 427, 2008.</ref>.
*[[Lupus pernio]]
*[[Lofgren syndrome]]
*[[Heerfordt syndrome]]
*[[Bilateral hilar adenopathy]] on [[CXR]] '''without''' symptoms
*Positive [[panda]] and/or [[lambda sign]] on [[gallium scan]]
==[[Pulmonary Function Tests]]==
* Significant amount of patients with pulmonary [[sarcoidosis]] will have a normal [[spirometry]] and [[lung volumes]] at the time of diagnosis, but over time some of these individuals will develope a [[restrictive pattern]], with reduction of [[lung volumes]]<ref>Baughman RP, Teirstein AS, Judson MA, et al: Clinical characteristics
of patients in a case control study of sarcoidosis. Am J Respir Crit Care Med 164:1885–1889, 2001.</ref><ref>Loddenkemper R, Kloppenborg A, Schoenfeld N, et al: Clinical indings in 715 patients with newly detected pulmonary sarcoidosis–results of a cooperative study in former West Germany and
Switzerland. WATL Study Group. Wissenschaftliche Arbeitsgemeinschaft fur die Therapie von Lungenkrankheitan. Sarcoidosis Vasc Diffuse Lung Dis 15(2):178–182, 1998.</ref><ref>Baughman RP, Winget DB, Bowen EH, Lower EE: Predicting respiratory failure in sarcoidosis patients. Sarcoidosis 14:154–158, 1997.</ref><ref>Judson MA, Baughman RP, Thompson BW, et al: Two year prognosis of sarcoidosis: the ACCESS experience. Sarcoidosis Vasc Diffuse Lung Dis 20(3):204–211, 2003.</ref>.
==References==
==References==
{{Reflist|2}}
{{Reflist|2}}

Latest revision as of 21:11, 10 May 2018

Sarcoidosis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Sarcoidosis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Sarcoidosis other diagnostic studies On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Sarcoidosis other diagnostic studies

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Sarcoidosis other diagnostic studies

CDC on Sarcoidosis other diagnostic studies

Sarcoidosis other diagnostic studies in the news

Blogs on Sarcoidosis other diagnostic studies

Directions to Hospitals Treating Sarcoidosis

Risk calculators and risk factors for Sarcoidosis other diagnostic studies

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Roshan Dinparasti Saleh M.D.


Overview

The diagnosis of sarcoidosis requires a tissue biopsy, with the exception of rare circumstances which the clinical findings are highly specific for sarcoidosis. The evaluation of pulmonary disease in sarcoidosis patients relies on three major factors: pulmonary function, chest imaging, and symptoms.

Tissue biopsy

The diagnosis of sarcoidosis requires a tissue biopsy, with the exception of rare circumstances which the clinical findings are highly specific for sarcoidosis[1]. It is ideal for biopsy to be minimally invasive and associated with the least morbidity. Thus, peripheral biopsy sites are preferred compared to visceral organs[2].When there is no evidence that a superficial peripheral site is involved by sarcoidosis, a biopsy is usually performed in organs which is very often the lung, because the lungs are involved in 90% of sarcoidosis patients[3].

Bronchoscopy

different samples can be taken with a bronchoscope:

Transbronchial biopsy(TBB)

Endobronchial biopsy

Transbronchial needle aspiration(TBNA)

Bronchoalveolar lavage(BAL)

  • is a complementary test for the diagnosis of pulmonary sarcoidosis[10]. BAL lymphocytosis(>15% lymphocytes) has a 90% sensivity[11]. BAL CD4/CD8 ratio is increased more than 3.5 in 50% of patients with pulmonary sarcoidosis[12][13][14].

Extrapulmonary tissue biopsy

Granulomas can be detected in any organ which is involved by sarcoidosis[2]

When the diagnosis can be made without performing a tissue biopsy?

in some clinical scenarios, the presentation is so specific that the diagnosis can be made without a confirmatory tissue biopsy[1].

Pulmonary Function Tests

References

  1. 1.0 1.1 Judson MA: The diagnosis of sarcoidosis. Clin Chest Med 29(3):415– 427, 2008.
  2. 2.0 2.1 Teirstein AS, Judson MA, Baughman RP, et al: The spectrum of biopsy sites for the diagnosis of sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 22(2):139 146, 2005.
  3. Baughman RP, Teirstein AS, Judson MA, et al: Clinical characteristics of patients in a case control study of sarcoidosis. Am J Respir Crit Care Med 164:1885–1889, 2001.
  4. Poe RH, Israel RH, Utell MJ, Hall WJ: Probability of a positive transbronchial lung biopsy result in sarcoidosis. Arch Intern Med 139(Jul):761–763, 1979.
  5. Koerner SK, Sakowitz AJ, Appelman RI, et al: Transbronchinal lung biopsy for the diagnosis of sarcoidosis. N Engl J Med 293(6):268–270, 1975.
  6. Gilman MJ, Wang KP: Transbronchial lung biopsy in sarcoidosis. An approach to determine the optimal number of biopsies. Am Rev Respir Dis 122(5):721–724, 1980.
  7. Shorr AF, Torrington KG, Hnatiuk OW: Endobronchial biopsy for sarcoidosis: a prospective study. Chest 120(1):109–114, 2001.
  8. Kieszko R, Krawczyk P, Michnar M, et al: The yield of endobronchial biopsy in pulmonary sarcoidosis: connection between spirometric impairment and lymphocyte subpopulations in bronchoalveolar lavage luid. Respiration 71(1):72–76, 2004.
  9. Agarwal R, Srinivasan A, Aggarwal AN, Gupta D: Eficacy and safety of convex probe EBUS-TBNA in sarcoidosis: a systematic review and meta-analysis. Respir Med 106(6):883–892, 2012.
  10. Meyer KC, Raghu G, Baughman RP, et al: An oficial American Thoracic Society clinical practice guideline: the clinical utility of bronchoalveolar lavage cellular analysis in interstitial lung disease. Am J Respir Crit Care Med 185(9):1004–1014, 2012.
  11. Drent M, van Nierop MA, Gerritsen FA, et al: A computer program using BALF-analysis results as a diagnostic tool in interstitial lung diseases. Am J Respir Crit Care Med 153(2):736–741, 1996.
  12. Welker L, Jorres RA, Costabel U, Magnussen H: Predictive value of BAL cell differentials in the diagnosis of interstitial lung diseases. Eur Respir J 24(6):1000–1006, 2004.
  13. Drent M, Wagenaar SS, Mulder PH, et al: Bronchoalveolar lavage fluid proiles in sarcoidosis, tuberculosis, and non-Hodgkin’s and Hodgkin’s disease. An evaluation of differences. Chest 105(2):514– 519, 1994.
  14. Winterbauer RH, Lammert J, Selland M, et al: Bronchoalveolar lavage cell populations in the diagnosis of sarcoidosis. Chest 104(2):352–361, 1993
  15. Baughman RP, Teirstein AS, Judson MA, et al: Clinical characteristics of patients in a case control study of sarcoidosis. Am J Respir Crit Care Med 164:1885–1889, 2001.
  16. Loddenkemper R, Kloppenborg A, Schoenfeld N, et al: Clinical indings in 715 patients with newly detected pulmonary sarcoidosis–results of a cooperative study in former West Germany and Switzerland. WATL Study Group. Wissenschaftliche Arbeitsgemeinschaft fur die Therapie von Lungenkrankheitan. Sarcoidosis Vasc Diffuse Lung Dis 15(2):178–182, 1998.
  17. Baughman RP, Winget DB, Bowen EH, Lower EE: Predicting respiratory failure in sarcoidosis patients. Sarcoidosis 14:154–158, 1997.
  18. Judson MA, Baughman RP, Thompson BW, et al: Two year prognosis of sarcoidosis: the ACCESS experience. Sarcoidosis Vasc Diffuse Lung Dis 20(3):204–211, 2003.

Template:WH Template:WS